Can a modified enzyme starve Hard-to-Treat blood cancers?

NCT ID NCT02732184

Completed Disease control Sponsor: Immedica Pharma AB Source: ClinicalTrials.gov ↗

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This phase 1 trial is testing an investigational drug called AEB1102 in adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has returned or stopped responding to standard treatments. AEB1102 is a modified human enzyme that breaks down arginine, an amino acid that cancer cells may depend on to grow. The study aims to find the highest safe dose and to see how the drug affects blood amino acid levels and whether it has any anti-tumor effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AEB1102 (Co-ArgI-PEG), a modified human enzyme designed to break down arginine, an amino acid that cancer cells may need to grow.
What this could lead to: If AEB1102 proves safe and shows anti-cancer activity, it could become a new treatment option for patients with hard-to-treat AML or MDS who have run out of standard options.
What could go wrong: This is an early, small phase 1 trial focused on safety and dosing, so it is not yet known if AEB1102 will effectively fight the cancer. Possible side effects are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA MYELODYSPLASTIC SYNDROME

Contacts and locations

Locations

Baylor Scott & White

Dallas, Texas, 75246, United States
Comprehensive Cancer Center at University of Michigan

Ann Arbor, Michigan, 48109, United States
Jewish General Hospital

Montreal, Quebec, Canada
Princess Margaret Cancer Centre

Toronto, Ontario, Canada
The Cleveland Clinic

Cleveland, Ohio, 44195, United States
University Hospitals Case Medical Center

Cleveland, Ohio, 44106, United States
University of Alberta

Edmonton, Alberta, Canada
University of Texas Southwestern Medical Center

Dallas, Texas, 75390, United States
Vanderbilt-Ingram Cancer Center

Nashville, Tennessee, 37232, United States
Washington University Medical School

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.